<DOC>
	<DOCNO>NCT00783367</DOCNO>
	<brief_summary>Pre-clinical data recently publish clinical data suggest synergistic effect lenalidomide dexamethasone . We hypothesize combination lenalidomide-dexamethasone overcome rituximab resistance . To determine response rate lenalidomide dexamethasone plus rituximab therapy subject recurrent small B-cell non-Hodgkin lymphoma lymphoma progression within 6 month treat rituximab alone rituximab-containing regimen , propose initial treatment drug two 28-day treatment cycle ( Part I ) . After response assessment follow two cycle lenalidomide-dexamethasone , patient enter Part II study . In Part II , patient receive lenalidomide-dexamethasone rituximab evaluate potential reversal rituximab resistance measure response rituximab progression-free survival follow rituximab .</brief_summary>
	<brief_title>Combination Therapy Using Lenalidomide ( Revlimid ) - Low Dose Dexamethasone Rituximab Treatment Rituximab-Resistant , Non-Aggressive B-Cell Lymphomas</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Previously treat , histologically confirm follicular lymphoma ( grade 1 , 2 , 3a ) , marginal zone lymphoma , small lymphocytic lymphoma less &lt; 5000 lymphocytes/mm3 lymphoplasmacytic lymphoma &lt; 3g/mL IgM , mantle cell lymphoma WHO classification Flow cytometry immunohistochemistry must document CD20 antigen expression . Past documentation CD20 antigen expression admissible . Subjects must treat rituximab combination chemotherapy monotherapy must refractory progressive disease &lt; 6 month first rituximab dose previous rituximab contain regimen At least 18 year age ECOG performance status 02 Measurable disease must present physical examination image study . Any tumor mass &gt; 2cm consider measurable . Lesions consider nonmeasurable , assessable include follow : bone lesion , ascites , pleural/pericardial effusion , lymphangitis cutis/pulmonis , bone marrow Patients history intravenous drug abuse behavior associate increase risk HIV infection test exposure HIV virus Understand voluntarily sign informed consent Able take aspirin ( 81 325 mg ) daily prophylactic anticoagulation ( patient intolerant ASA may use warfarin low molecular weight heparin ) Laboratory test result within range : absolute neutrophil count great equal 1500/mm3 ; platelet count great equal 75,000/mm3 ; serum creatinine less equal 2.0mg/dL ; total bilirubin less equal 1.5mg/dL ( unless due Gilbert 's syndrome ) ; AST ( SGOT ) ALT ( SGPT ) less equal 2.5 x ULN le equal 5 x ULN hepatic metastasis present Disease free prior malignancy great equal 5 year exception currently treat basal cell squamous cell carcinoma skin , carcinoma `` situ '' cervix breast All study participant must register mandatory RevAssist program , willing able comply requirement RevAssist Females childbearing potential ( FCBP ) must negative serum urine pregnancy test sensitivity least 50 mIU/mL within 1014 day prior within 24 hour prescribe lenalidomide ( prescription must fill within 7 day ) must either commit continued abstinence heterosexual intercourse begin TWO acceptable method birth control , one highly effective method one additional effective method AT THE SAME TIME , least 28 day start take lenalidomide . FCBP must also agree ongoing pregnancy test . Men must agree use latex condom sexual contact FCBP even successful vasectomy . Any serious medical condition , laboratory abnormality , psychiatric illness would prevent subject follow study procedure Pregnant breastfeeding female Any condition , include presence laboratory abnormality , place subject unacceptable risk he/she participate study confounds ability interpret data study Use experimental drug therapy within 28 day baseline Known hypersensitivity thalidomide The development erythema nodosum characterize desquamate rash take thalidomide similar drug Any prior use lenalidomide Known positivity HIV active infectious Hepatitis , type A , B , C. Patients test positive know infected eligible due increase risk infection regimen . HIV test require study entry , require patient perceive risk . Known central nervous system involvement lymphoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Revlimid</keyword>
	<keyword>Celgene brand lenalidomide</keyword>
	<keyword>lenalidomide</keyword>
	<keyword>Rituxan</keyword>
	<keyword>CD20 antibody , rituximab</keyword>
	<keyword>rituximab</keyword>
	<keyword>Follicular Lymphoma</keyword>
	<keyword>Marginal Zone B-Cell Lymphoma</keyword>
	<keyword>Lymphoma , Small Lymphocytic</keyword>
	<keyword>Waldenstrom Macroglobulinemia</keyword>
	<keyword>Mantle-Cell Lymphoma</keyword>
	<keyword>Antigens , CD20</keyword>
	<keyword>refractory</keyword>
	<keyword>resistantRefractory/progressive lymphoma le 6 month first rituximab dose previous rituximab-containing regimen</keyword>
	<keyword>Previously treat</keyword>
	<keyword>Treated rituximab</keyword>
</DOC>